InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
69,618.94
(
0.20%
)
Post# of 253509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

acgood

Send PM Follow Ignore
Followers 18
Posts 1093
Boards Moderated 0
Alias Born 05/12/2007

acgood

Re: ghmm post# 137722

Thursday, 02/23/2012 8:59:57 PM

Thursday, February 23, 2012 8:59:57 PM

Post# of 253509
LGND preclinical hepdirect HCV inhibitor

I haven't read the 10k yet. But:

-there was an MBRX hepdirect HCV asset previously licensed to Roche - made it to phase 1 (not sure of the target of the drug)

-worldwide rights to all hepdirect assets for HCV already have been licensed to Chiva

-I would be shocked in LGND was investing anything in any hepdirect asset currently.

Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up